BURLINGAME, CA — Color Genomics has secured a $45 million investment led by General Catalyst with participation from Bono, lead singer of U2, and existing investors including Susan L. Wagner, 8VC, Khosla Ventures and Emerson Collective. The company also welcomes Susan L. Wagner, co-founder, former vice chairman, and chief operating officer of BlackRock and Hemant Taneja, managing director at General Catalyst, to its board of directors.
Color Genomics provides consumers access to their genetic information. The company’s Color Test is physician-ordered and comes with free board-certified genetic counseling for clients and healthcare providers. The 30-gene Color Test analyzes genes closely associated with some of the most common hereditary cancers: breast, colorectal, melanoma, ovarian, pancreatic, prostate, stomach, and uterine cancers.
“We’re in the middle of one of the greatest shifts seen in health. Increased access to genetic information is enabling doctors and their patients to create personalized plans for better prevention, detection and treatment of hereditary disease,” said Elad Gil, CEO and co-founder of Color Genomics. “The new funding will go toward bringing even more people access to potentially life-saving genetic information and building the open databases necessary to further global research and development around major diseases.”
The latest investment brings Color’s total funding to $60 million. The company was founded in 2015.